Adamas Pharmaceuticals granted FDA approval for GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
GOCOVRI is expected to be available in the fourth quarter, and formally launched with the full deployment of Adamas's sales force in January 2018.
No comments:
Post a Comment